Santaris Pharma A/S ' Product Pipeline Review ' 2012

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Santaris Pharma A/S ' Product Pipeline Review ' 2012
Published on August 2012

Report Summary


Summary

Global Markets Direct's pharmaceuticals report, 'Santaris Pharma A/S - Product Pipeline Review - 2012' provides data on the Santaris
Pharma A/S's research and development focus. The report includes information on current developmental pipeline, complete with
latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Santaris Pharma A/S's
corporate website, SEC filings, investor presentations and featured press releases, both from Santaris Pharma A/S and
industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- Santaris Pharma A/S - Brief Santaris Pharma A/S overview including business description, key information and facts, and its
locations and subsidiaries.
- Review of current pipeline of Santaris Pharma A/S human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities,
across the globe.
- Product profiles for late stage and clinical stage products of Santaris Pharma A/S with complete description of the product's
developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Santaris Pharma A/S's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Santaris Pharma A/S's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Santaris Pharma A/S in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Santaris Pharma A/S's R&D portfolio and develop key strategic initiatives to
reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Santaris Pharma A/S.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Santaris Pharma A/S and identify potential opportunities in those areas.

Santaris Pharma A/S ' Product Pipeline Review ' 2012 (From Slideshare) Page 1/7


Table of Content

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Santaris Pharma A/S Snapshot 6
Santaris Pharma A/S Overview 6
Key Information 6
Key Facts 6
Santaris Pharma A/S ' Research and Development Overview 7
Key Therapeutic Areas 7
Santaris Pharma A/S ' Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products ' Monotherapy 11
Pipeline Products ' Combination Treatment Modalities 12
Santaris Pharma A/S ' Pipeline Products Glance 13
Santaris Pharma A/S Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
Santaris Pharma A/S ' Early Stage Pipeline Products 15
Pre-Clinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
Santaris Pharma A/S ' Drug Profiles 17
Anticancer Drug 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Drug For Cardivascular Disease 18
R&D Progress 18
Drug For Viral Diseases 19
R&D Progress 19
EZN-2968 20
R&D Progress 20
EZN-3892 21
R&D Progress 21
EZN-4176 22



R&D Progress 22
EZN-4176 + MDV-3100 24
R&D Progress 24
EZN3920 26
R&D Progress 26
PEG-SN38 + Avastin 28
R&D Progress 28
SPC3649 29
R&D Progress 29
SPC4955 30
R&D Progress 30
Santaris Pharma A/S ' Pipeline Analysis 31
Santaris Pharma A/S ' Pipeline Products by Therapeutic Class 31
Santaris Pharma A/S ' Pipeline Products by Route of Administration 32
Santaris Pharma A/S ' Pipeline Products By Mechanism of Action 33
Santaris Pharma A/S ' Recent Pipeline Updates 34
Santaris Pharma A/S - Dormant Projects 37
Santaris Pharma A/S - Discontinued Pipeline Products 38
Discontinued Pipeline Product Profiles 38
ENZ-3042 38
Santaris Pharma A/S ' Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Santaris Pharma A/S, Recent Developments 40
Santaris Pharma A/S- Press Release 40
Apr 19, 2012: Santaris Pharma Presents Final Phase IIa Study Results For Miravirsen Showing Dose-Dependent, Prolonged Antiviral
Activity In Hepatitis C Patients 40
Dec 03, 2009: Santaris Announces The Development Of SPC3649 For The Treatment Of Hepatitis C Virus (HCV) Infections In
Chimpanzees 41
Jun 04, 2009: LNA-Based HIF-1 Alpha Inhibitor Shows Early Signs Of Clinical Benefit 42
Jun 01, 2009: Enzon Presents Clinical Data From HIF-1 Alpha Antagonist Study At ASCO 42
Mar 20, 2009: Another LNA-based RNA Inhibitor Enters Clinical Trials 43
Mar 20, 2009: Santaris Pharma Announces That The Fourth LNA-Based Drug Has Been Brought Into The Clinic 44
Feb 10, 2009: Enzon Announces IND Acceptance For Its Survivin Antagonist 45
Financial Deals Landscape 46
Santaris Pharma A/S, Deals Summary 46
Santaris Pharma A/S, Pharmaceuticals & Healthcare, Deal Details 48



Venture Financing 48
Santaris Pharma Secures $30 Million In Series C Financing 48
Santaris Pharma Secures $48.3 Million In Venture Financing 51
Partnerships 54
Santaris Pharma Expands Its Collaboration With Pfizer 54
Santaris Pharma Enters Into Strategic Alliance With miRagen Therapeutics 56
Shire Enters Into Research Agreement With Santaris Pharma 58
Wyeth Pharma Enters Into An Agreement With Santaris Pharma 60
GlaxoSmithKline Enters Into An Agreement With Santaris Pharma 61
Enzon Pharma Signs Agreement With Santaris Pharma 63
Santaris Pharma Enters Into Research Agreement With University of Copenhagen 65
Licensing Agreements 66
Santaris Pharma Enters Into Licensing Agreement With Massachusetts General Hospital 66
Equity Offering 67
Santaris Pharma Completes Private Placement Of $5 Million 67
Appendix 68
Methodology 68
Coverage 68
Secondary Research 68
Primary Research 68
Expert Panel Validation 68
Contact Us 69
Disclaimer 69

List of Tables

Santaris Pharma A/S, Key Information 6
Santaris Pharma A/S, Key Facts 6
Santaris Pharma A/S ' Pipeline by Indication, 2012 9
Santaris Pharma A/S ' Pipeline by Stage of Development, 2012 10
Santaris Pharma A/S ' Monotherapy Products in Pipeline, 2012 11
Santaris Pharma A/S ' Combination Treatment Modalities in Pipeline, 2012 12
Santaris Pharma A/S ' Phase II, 2012 13
Santaris Pharma A/S ' Phase I, 2012 14
Santaris Pharma A/S ' Pre-Clinical, 2012 15
Santaris Pharma A/S ' Discovery, 2012 16
Santaris Pharma A/S ' Pipeline By Therapeutic Class, 2012 31
Santaris Pharma A/S ' Pipeline By Route of Administration, 2012 32
Santaris Pharma A/S ' Pipeline Products By Mechanism of Action, 2012 33
Santaris Pharma A/S ' Recent Pipeline Updates, 2012 34
Santaris Pharma A/S - Dormant Developmental Projects,2012 37
Santaris Pharma A/S - Discontinued Pipeline Products, 2012 38
Santaris Pharma A/S, Other Locations 39
Santaris Pharma A/S, Deals Summary 46
Santaris Pharma Secures $30 Million In Series C Financing 48
Santaris Pharma Secures $48.3 Million In Venture Financing 51
Santaris Pharma Expands Its Collaboration With Pfizer 54
Santaris Pharma Enters Into Strategic Alliance With miRagen Therapeutics 56



Shire Enters Into Research Agreement With Santaris Pharma 58
Wyeth Pharma Enters Into An Agreement With Santaris Pharma 60
GlaxoSmithKline Enters Into An Agreement With Santaris Pharma 61
Enzon Pharma Signs Agreement With Santaris Pharma 63
Santaris Pharma Enters Into Research Agreement With University of Copenhagen 65
Santaris Pharma Enters Into Licensing Agreement With Massachusetts General Hospital 66
Santaris Pharma Completes Private Placement Of $5 Million 67

List of Figures

Santaris Pharma A/S ' Pipeline by Indication, 2012 8
Santaris Pharma A/S ' Pipeline by Stage of Development, 2012 10
Santaris Pharma A/S ' Monotherapy Products in Pipeline, 2012 11
Santaris Pharma A/S ' Combination Treatment Modalities in Pipeline, 2012 12
Santaris Pharma A/S ' Pipeline By Therapeutic Class, 2012 31
Santaris Pharma A/S ' Pipeline By Route of Administration, 2012 32
Santaris Pharma A/S - Pipeline Products By Mechanism of Action, 2012 33


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.


Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 1 500.00 Quantity: _____

Site License--USD 3 000.00 Quantity: _____

Corporate License--USD 4 500.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Santaris Pharma A/S ' Product Pipeline Review ' 2012

Recommended

Recommended

More Related Content

More from ReportLinker.com

More from ReportLinker.com (20)

Santaris Pharma A/S ' Product Pipeline Review ' 2012